Cargando…

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors

BACKGROUND: Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed. METHODS: Here, we compared BCG antitumoral efficacy with another live attenuat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreo, Eduardo, Uranga, Santiago, Picó, Ana, Gómez, Ana Belén, Nardelli-Haefliger, Denise, del Fresno, Carlos, Murillo, Ingrid, Puentes, Eugenia, Rodríguez, Esteban, Vales-Gómez, Mar, Pardo, Julian, Sancho, David, Martín, Carlos, Aguilo, Nacho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252205/ https://www.ncbi.nlm.nih.gov/pubmed/35781395 http://dx.doi.org/10.1136/jitc-2021-004325

Ejemplares similares

Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung
por: Moreo, Eduardo, et al.
Publicado: (2023)

BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro
por: Esteso, Gloria, et al.
Publicado: (2022)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG
por: Esteso, Gloria, et al.
Publicado: (2021)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis
por: Aguilo, Nacho, et al.
Publicado: (2017)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo
por: Uranga, Santiago, et al.
Publicado: (2016)

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
por: Nguyen, Sylvain, et al.
Publicado: (2022)

Cell death induced by cytotoxic CD8(+) T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
por: Jaime-Sanchez, Paula, et al.
Publicado: (2020)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages
por: Gonzalo-Asensio, Jesús, et al.
Publicado: (2018)

Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment
por: Tarancón, Raquel, et al.
Publicado: (2021)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product
por: Hozouri, Hamidreza, et al.
Publicado: (2014)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Protective role of intravesical BCG in COVID-19 severity
por: Gallegos, Héctor, et al.
Publicado: (2021)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies
por: Broset, Esther, et al.
Publicado: (2021)

IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
por: Aguilo, Nacho, et al.
Publicado: (2016)

Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis
por: Roy, Alvaro, et al.
Publicado: (2019)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

BCGitis: A rare complication after intravesical BCG therapy
por: Oliveira, Maria João, et al.
Publicado: (2015)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Reactive Arthritis – A Rare Complication of Intravesical BCG Instillation
por: Freixa, Marta, et al.
Publicado: (2020)

ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question
por: Aguiló, Nacho, et al.
Publicado: (2013)

Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG)
por: Gomez, Eric, et al.
Publicado: (2009)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_n2bkka7f117bm3okmplea8l5nt